Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

NCT06696183 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

AML - Acute Myeloid Leukemia

Interventions

DRUG: Gilteritinib (GILT)
DRUG: Venetoclax (VEN)
DRUG: Azacitidine (AZA)

Sponsor

Technische Universität Dresden